Numerical defect of circulating dendritic cell subsets and defective dendritic cell generation from monocytes of patients with advanced melanoma

Cancer Letters

Volumn 337, Issue 2, 2013, Pages 184-192

  Failli, Alessandra ^a   Legitimo, Annalisa ^a   Orsini, Giulia ^a   Romanini, Antonella ^b   Consolini, Rita ^a  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF PISA   (Italy)

Author keywords

Circulating dendritic cells; Generation of dendritic cells; Immunotherapy; Melanoma

Indexed keywords

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER GROWTH; CELL COUNT; CELL MATURATION; CELL PROLIFERATION; CELL SUBPOPULATION; CLINICAL ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN CELL; IMMUNOPATHOGENESIS; IMMUNOSURVEILLANCE; MALE; MELANOMA; MONOCYTE; MYELOID DENDRITIC CELL; PATIENT SELECTION; PHAGOCYTOSIS; PHENOTYPE; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL;

CIRCULATING DENDRITIC CELLS; GENERATION OF DENDRITIC CELLS; IMMUNOTHERAPY; MELANOMA;

ADULT; AGED; CASE-CONTROL STUDIES; CELL COUNT; CELL SHAPE; CELLS, CULTURED; COCULTURE TECHNIQUES; DENDRITIC CELLS; DEXTRANS; DISEASE PROGRESSION; DOWN-REGULATION; ENDOCYTOSIS; FEMALE; FLUORESCEIN-5-ISOTHIOCYANATE; HUMANS; IMMUNOTHERAPY; LECTINS, C-TYPE; LYMPHOCYTE ACTIVATION; LYMPHOCYTE CULTURE TEST, MIXED; MALE; MANNOSE-BINDING LECTINS; MELANOMA; MIDDLE AGED; MONOCYTES; NEOPLASM STAGING; PHAGOCYTOSIS; PHENOTYPE; RECEPTORS, CELL SURFACE; SKIN NEOPLASMS; T-LYMPHOCYTES; TIME FACTORS; TUMOR ESCAPE;

EID: 84880512886     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.05.013     Document Type: Article

References (57)

1. Polak M.E., Borthwick N.J., Gabrie F.G., Johnson P., Higgins B., Hurren J., McCormick D., Jager M.J., Cree I.A. Mechanisms of local immunosuppression in cutaneous melanoma. Br. J. Cancer 2007, 96:1879-1887.
2. Sabado R.L., Bhardwaj N. Directing dendritic cell immunotherapy towards successful cancer treatment. Immunotherapy 2010, 2:37-56.
3. Charles J., Di Domizio J., Salameire D., Bendriss-Vermare N., Aspord C., Muhammad R., Lefebvre C., Plumas J., Leccia M.T., Chaperot L. Characterization of circulating dendritic cells in melanoma: role of CCR6 in plasmacytoid dendritic cell recruitment to the tumor. J. Invest. Dermatol. 2010, 130:1646-1656.
4. Gervais A., Levêque J., Bouet-Toussaint F., Burtin F., Lesimple T., Sulpice L., Patard J.J., Genetet N., Catros-Quemener V. Dendritic cells are defective in breast cancer patients: a potential role for polyamine in this immunodeficiency. Breast Cancer Res. 2005, 7:R326-R335.
5. Gulubova M.V., Ananiev J.R., Vlaykova T.I., Yovchev Y., Tsoneva V., Manolova I.M. Role of dendritic cells in progression and clinical outcome of colon cancer. Int. J. Colorectal. Dis. 2012, 27:159-169.
6. Pinzon-Charry A., Maxwell T., Prato S., Furnival C., Schmidt C., López J.A. HLA-DR+ immature cells exhibit reduced antigen-presenting cell function but respond to CD40 stimulation. Neoplasia 2005, 7:1123-1132.
7. Lenahan C., Avigan D. Dendritic cell defects in patients with cancer: mechanisms and significance. Breast Cancer Res. 2006, 8:101.
8. Shin S., Jang J.Y., Roh E.Y., Yoon J.H., Kim J.S., Han K.S., Kim S., Yun Y., Choi S.Y., Choi J.D., Kim S.H., Kim S.J., Song E.Y. Differences in circulating dendritic cell subtypes in pregnant women, cord blood and healthy adult women. J. Korean Med. Sci. 2009, 24:853-859.
9. Steinman R.M. Some interfaces of dendritic cell biology. APMIS 2003, 111:675-697.
10. Sciarra A., Lichtner M., Autran G.A., Mastroianni C., Rossi R., Mengoni F., Cristini C., Gentilucci A., Vullo V., Di Silverio F. Characterization of circulating blood dendritic cell subsets DC123+ (lymphoid) and DC11C+ (myeloid) in prostate adenocarcinoma patients. Prostate 2007, 67:1-7.
11. Shortman K., Liu Y.J. Mouse and human dendritic cell subtypes. Nat. Rev. Immunol. 2002, 2:151-161.
12. MacDonald K.P.A., Munster D.J., Clark G.J., Dzionek A., Schimitz J., Hart D.J. Characterization of human blood dendritic cells subsets. Blood 2002, 100:4512-4520.
13. Kim R., Emi M., Tanabe K., Arihiro K. Potential functional role of plasmacytoid dendritic cells in cancer immunity. Immunology 2007, 121:149-157.
14. Pinzon-Charry A., Maxwell T., López J.A. Dendritic cell dysfunction in cancer: a mechanism for immunosuppression. Immunol. Cell. Biol. 2005, 83:451-461.
15. Hoffman T.K., Muller-Berghaus J., Ferris R.L., Johnson J.T., Storkus W.J., Whiteside T.L. Alterations in the frequency of dendritic cell subsets in the peripheral circulation of patients with squamous cell carcinomas of the head and neck. Clin. Cancer Res. 2002, 8:1787-1793.
16. Lissoni P., Vigore L., Ferranti R., Bukovec R., Meregalli S., Mandala M., Barni S., Tancini G., Fumagalli L., Giani L. Circulating dendritic cells in early and advanced cancer patients: diminished percent in the metastatic disease. J. Biol. Regul. Homeost. Agents 1999, 13:216-219.
17. Lissoni P., Malugani F., Bonfanti A., Bucovec R., Secondino S., Brivio F., Ferrari-Bravo A., Ferrante R., Vigoré L., Rovelli F., Mandalà M., Viviani S., Fumagalli L., Gardani G.S. Abnormally enhanced blood concentrations of vascular endothelial growth factor (VEGF) in metastatic cancer patients and their relation to circulating dendritic cells, IL-12 and endothelin-1. J. Biol. Regul. Homeost Agents 2001, 15:140-144.
18. Hasskamp J., Zapas J., Elias G. Dendritic cells in patients with melanoma. Ann. Surg. Oncol. 2008, 15:1807.
19. McCarter M.D., Baumgartner J., Escobar G.A., Richter D., Lewis K., Robinson W., Wilson C., Palmer B.E., Gonzalez R. Immunosuppressive dendritic and regulatory T cells are upregulated in melanoma patients. Ann. Surg. Oncol. 2007, 10:2854-2860.
20. Dhodapkar M.V., Dhodapkar K.M., Palucka K. Interactions of tumor cells with dendritic cells: balancing immunity and tolerance. Cell Death Differ. 2008, 15:39-50.
21. Orsini G., Legitimo A., Failli A., Massei F., Biver P., Consolini R. Enumeration of human peripheral blood dendritic cells throughout the life. Int. Immunol. 2012, 24:347-356.
22. Legitimo A., Consolini R., Failli A., Fabiano S., Bencivelli W., Scatena F., Mosca F. In vitro treatment of monocytes with 8-methoxypsolaren and ultraviolet A light induces dendritic cells with a tolerogenic phenotype. Clin. Exp. Immunol. 2007, 148:564-572.
23. Failli A., Legitimo A., Mazzoni A., Urbani L., Scatena F., Mosca F., Consolini R. The combination of immunosuppressive drugs with 8-methoxypsoralen and ultraviolet a light modulates the myeloid-derived dendritic cell function. Int. J. Immunopathol. Pharmacol. 2011, 24:89-99.
24. Mucci I., Legitimo A., Compagnino M., Consolini R., Migliaccio P., Metelli M.R., Scatena F. The methodological approach for the generation of human dendritic cells from monocytes affects the maturation state of the resultant dendritic cells. Biologicals 2009, 37:288-296.
25. Whiteside T.L. Immune suppression in cancer. Effects on immune cells, mechanisms and future therapeutic intervention. Semin. Cancer Biol. 2006, 16:3-15.
26. Mohty M., Isnardon D., Vey N., Brière F., Blaise D., Olive D., Gaugler B. Low blood dendritic cells in chronic myeloid leukaemia patients correlates with loss of CD34+/CD38-primitive haematopoietic progenitors. Br. J. Haematol. 2002, 119:115-118.
27. Ratta M., Fagnoni F., Curti A., Vescovini R., Sansoni P., Oliviero B., Fogli M., Ferri E., Della Cuna G.R., Tura S., Baccarani M., Lemoli R.M. Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6. Blood 2002, 100:230-237.
28. Boissel N., Rousselot P., Raffoux E., Cayuela J.M., Maarek O., Charron D., Degos L., Dombret H., Toubert A., Rea D. Defective blood dendritic cells in chronic myeloid leukemia correlate with high plasmatic VEGF and are not normalized by imatinib mesylate. Leukemia 2004, 18:1656-1661.
29. Mami N.B., Mohty M., Chambost H., Gaugler B., Olive D. Blood dendritic cells in patients with acute lymphoblastic leukaemia. Br. J. Haematol. 2004, 126:77-80.
30. van Cruijsen H., Hoekman K., Stam A.G., van den Eertwegh A.J., Kuenen B.C., Scheper R.J., Giaccone G., de Gruijl T.D. Defective differentiation of myeloid and plasmacytoid dendritic cells in advanced cancer patients is not normalized by tyrosine kinase inhibition of the vascular endothelial growth factor receptor. Clin. Dev. Immunol. 2007, 17315.
31. Pinzon-Charry A., Ho C.S., Maxwell T., McGuckin M.A., Schmidt C., Furnival C., Pyke C.M., López J.A. Numerical and functional defects of blood dendritic cells in early- and late-stage breast cancer. Br. J. Cancer 2007, 97:1251-1259.
32. Beckebaum S., Zhang X., Chen X., Yu Z., Frilling A., Dworacki G., Grosse-Wilde H., Broelsch C.E., Gerken G., Cicinnati V.R. Increased levels of interleukin-10 in serum from patients with hepatocellular carcinoma correlate with profound numerical deficiencies and immature phenotype of circulating dendritic cell subsets. Clin. Cancer Res. 2004, 10:7260-7269.
33. Baumgartner J.M., Jordan K.R., Hu L.J., Wilson C.C., Banerjee A., McCarter M.D. DC maturation and function are not altered by melanoma-derived immunosuppressive soluble factors. J. Surg. Res. 2012, 176:301-308.
34. Ferrantini M., Capone I., Belardelli F. Dendritic cells and cytokines in immune rejection of cancer. Cytokine Growth Factor Rev. 2008, 19:93.
35. Lou Y., Liu C., Kim G.J., Liu Y.J., Hwu P., Wang G. Plasmacytoid dendritic cells synergize with myeloid dendritic cells in the induction of antigen-specific antitumor immune responses. J. Immunol. 2007, 178:1534-1541.
36. Salio M., Cella M., Vermi W., Facchetti F., Palmowski M.J., Smith C.L., Shepherd D., Colonna M., Cerandolo V. Plasmacytoid dendritic cells prime IFN-γ-secreting melanoma-specific CD8 lymphocytes and are found inprimary melanoma lesions. Eur. J. Immunol. 2003, 33:1052-1062.
37. Hartmann E., Wollenberg B., Rothenfusser S., Wagner M., Wellisch D., Mack B., Giese T., Gires O., Endres S., Hartmann G. Identification and functional analysis of tumor-infiltrating plasmacytoid dendritic cells in head and neck cancer. Cancer Res. 2003, 63:6478-6487.
38. Zou W., Machelon V., Coulomb-L'Hermin A., Borvak J., Nome F., Isaeva T., Wei S., Krzysiek R., Durand-Gasselin I., Gordon A., Pustilnik T., Curiel D.T., Galanaud P., Capron F., Emilie D., Curiel T.J. Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nat. Med. 2001, 7:1339-1346.
39. Treilleux I., Blay J.Y., Bendriss-Vermare N., Ray-Coquard I., Bachelot T., Guastalla J.P., Bremond A., Goddard S., Pin J.J., Barthelemy-Dubois C., Lebecque S. Dendritic cell infiltration and prognosis of early stage breast cancer. Clin. Cancer Res. 2004, 10:7466-7474.
40. Weigel B.J., Nath N., Taylor P.A., Panoskaltsis-Mortari A., Chen W., Krieg A.M., Brasel K., Blazar B.R. Comparative analysis of murine marrow-derived dendritic cells generated by Flt3L or GM-CSF/IL-4 and matured with immune stimulatory agents on the in vivo induction of antileukemia responses. Blood 2002, 100:4169-4176.
41. Palamara F., Meindl S., Holcmann M., Luhrs P., Stingl G., Sibilia M. Identification and characterization of pDC-like cells in normal mouse skin and melanomas treated with imiquimod. J. Immunol. 2004, 173:3051-3306.
42. Aspord C., Leccia M.T., Salameire D., Laurin D., Chaperot L., Charles J., Plumas J. HLA-A(*)0201(+) plasmacytoid dendritic cells provide a cell-based immunotherapy for melanoma patients. J. Invest. Dermatol. 2012, 132:2395-2406.
43. Drobits B., Holcmann M., Amberg N., Swiecki M., Grundtner R., Hammer M., Colonna M., Sibilia M. Imiquimod clears tumors in mice independent of adaptive immunity by converting pDCs into tumor-killing effector cells. J. Clin. Invest. 2012, 122:575-585.
44. Peng J.C., Thomas R., Dredge K. Dendritic cell immunotherapy for melanoma. Rev. Recent Clin. Trials 2006, 1:87-102.
45. Schuler G. Dendritic cell vaccination in melanoma. Melanoma Res. e-Suppl. 2010, 20.
46. Poschke I., Mao Y., Adamson L., Salazar-Onfray F., Masucci G., Kiessling R. Myeloid-derived suppressor cells impair the quality of dendritic cell vaccines. Cancer Immunol. Immunother. 2011, 61:827-838.
47. Brimnes M.K., Vangsted A.J., Knudsen L.M., Gimsing P., Gang A.O., Johnsen H.E., Svane I.M. Increased level of both CD4+FOXP3+ regulatory T cells and CD14+HLA-DR/low myeloid-derived suppressor cells and decreased level of dendritic cells in patients with multiple myeloma. Scand. J. Immunol. 2010, 72:540-547.
48. Filipazzi P., Valenti R., Huber V., Pilla L., Canese P., Iero M., Castelli C., Mariani L., Parmiani G., Rivoltini L. IdentiWcation of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J. Clin. Oncol. 2007, 25:2546-2553.
49. Gustafson M.P., Lin Y., New K.C., Bulur P.A., O'Neill B.P., Gastineau D.A., Dietz A.B. Systemic immune suppression in glioblastoma: the interplay between CD14+HLA-DRlo/neg monocytes, tumor factors, and dexamethasone. Neuro Oncol. 2010, 12:631-644.
50. Hoechst B., Ormandy L.A., Ballmaier M., Lehner F., Kruger C., Manns M.P., Greten T.F., Korangy F. A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells. Gastroenterology 2008, 135:234-243.
51. Lin Y., Gustafson M.P., Bulur P.A., Gastineau D.A., Witzig T.E., Dietz A.B. Immunosuppressive CD14+HLA-DR(low)/¡ monocytes in B-cell non-Hodgkin lymphoma. Blood 2011, 117:872-881.
52. Mirza N., Fishman M., Fricke I., Dunn M., Neuger A.M., Frost T.J., Lush R.M., Antonia S., Gabrilovich D.I. All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients. Cancer Res. 2006, 66:9299-9307.
53. Poschke I., Mougiakakos D., Hansson J., Masucci G.V., Kiessling R. Immature immunosuppressive CD14+HLA-DR¡/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign. Cancer Res. 2010, 70:4335-4345.
54. Schmielau J., Finn O.J. Activated granulocytes and granulocyte- derived hydrogen peroxide are the underlying mechanism of suppression of T-cell function in advanced cancer patients. Cancer Res. 2001, 61:4756-4760.
55. Vuk-Pavlovic S., Bulur P.A., Lin Y., Qin R., Szumlanski C.L., Zhao X., Dietz A.B. Immunosuppressive CD14+HLA-DRlow/¡ monocytes in prostate cancer. Prostate 2010, 70:443-455.
56. Gabrilovich D.I., Corak J., Ciernik I.F., Kavanaugh D., Carbone D.P. Decreased antigen presentation by dendritic cells in patients with breast cancer. Clin. Cancer Res. 1997, 3:483-490.
57. Cheng P., Corzo C.A., Luetteke N., Yu B., Nagaraj S., Bui M.M., Ortiz M., Nacken W., Sorg C., Vogl T., Roth J., Gabrilovich D.I. Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J. Exp. Med. 2008, 205:2235-2249.